Biosimilar Manufacturing solution center

  1. Dancing In The Bioprocessing Ballroom: Voices Of Experience

    Single-use technology is well-established, and has made its way into commercial licensed facilities, but there is more innovation in this field which will further enhance its versatility into new markets and technologies. The closed-system ballroom manufacturing approach will enable biomanufacturers to take full advantage of the flexibility offered by single-use systems, while driving out risk and is particularly suitable for applications that require multiple or rapid change-overs, and therapies with small scale production.  

  2. Staying Flexible In Biomanufacturing

    The concept of optionality is key to staying flexible in biomanufacturing by keeping your options open and having multiple pathways to take while navigating through this highly uncertain environment. Using a combination of financial options analysis and decision analytics to quantify your options helps to embrace the uncertainty equation.  

  3. Evolution of Single-Use Bioprocessing Into BioPharm 4.0

    Using data analytics to drive continuous improvements in efficiency.

  4. Amgen’s Digital Transformation: Linking Raw Material Data From Suppliers To Patients

    Using its Supplier Relationship Excellence (SRE) program, Amgen opened the lines of communication with suppliers and created a feedback loop where data can be shared to better understand operational performance. 

  5. Market Research Report: Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)

    A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of the market. ISR’s Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition) goes into depth on one of the most important aspects of biosimilars: manufacturing.

  6. How Biopharma Is Capitalizing On The Antibody Boom

    Antibodies continue to dominate. Analyzing the strategies employed by successful players in the field could provide invaluable lessons for those hoping to enter it.

  7. Embracing Biosimilars, They Are Here To Stay

    The biosimilars market is suddenly booming, with established biopharma giants and nimble start-ups all clamoring for a piece of the action. But such steep competition means that only the wise will survive.

  8. Multidimensional Scale-Up Of A Monoclonal Antibody Capture Step Contributes To Shortened Time To Market

    Fast and efficient process development and scale-up contributes to a shortened time to market. This application note demonstrates a multidimensional scale-up (change of both column diameter and bed height) of a mAb capture step, using the ÄKTA pilot 600 chromatography system.

  9. Process-Economy Simulation Of mAb Capture Step With Protein A Chromatography Resin

    Calculation examples that highlight scenarios where the enhanced capacity and alkaline‑stability of MabSelect PrismA can provide process economic benefits to large‑scale mAb processing.

  10. Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations

    I sat down with Kate Hammeke, VP of Industry Standard Research to discuss the biggest surprises or takeaways from this year’s report about the industry’s biologics and biosimilars manufacturing goals. But the conversation also evolved to some of the larger trends Hammeke expects to see impacting the biosimilar players in the future.